(Total Views: 412)
Posted On: 03/15/2019 1:01:36 PM
Post# of 72436
Seems like a good time to add, given recent developments. If Non US Pharma gets the non US markets for 50% let's say, it makes sense the trial design for EU would be most likely the last consideration before signing a deal.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)